Psychedelic Bulletin

Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.

Natural Medicine Advisory Bulletin #3: August 2023

Five of six subcommittees plus the full Natural Medicine Advisory Board (NMAB) met in August. Harm Reduction and Public Safety did not meet and was dissolved by the full NMAB on August 18th. Updates from each subcommittee that met, as well as the Natural Medicine Advisory Board, are shared in this Issue.

Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection

This week: will MAPS PBC’s MDMA drug product be called ‘RENSANSE’?; We look at Sage’s Zuranolone flop; DEA throws a potential lifeline to at-home ketamine providers; UK Parliamentary Office publishes note on psychedelics; and lots more…

Psychedelic Bulletin #142: Terran’s IP Portfolio; AMA Advocates Against Non-Medical Psychedelics; Couple Receives First Psilocybin Services in Oregon; Mass. Ballot Measure Ramps Up; NIDA and NIMH Directors Opine

This week: we take a deep dive into Terran Biosciences’ IP portfolio and apparent strategy; a psychedelic naive couple are the first people to receive legal psilocybin services in OR; AMA, NIDA and NIMH opine on psychedelics; a psychedelic ballot measure heats up in Mass.; and lots more…